GLPwatch
[Glucagon-like peptide 1 agonists : the fourth pillar of nephroprotection in type 2 diabetes].
Rev Med Suisse · 2025
Last updated 2026-05-28A study found that weekly injections of semaglutide (1 mg) in people with type 2 diabetes and moderate to severe kidney disease reduced the risk of major kidney problems by 24% over 3.4 years, and lowered the risk of death from any cause by 20%. The treatment also showed potential benefits in reducing overall mortality, though further research is needed on tirzepatide. Side effects like stomach issues and muscle loss were noted, so careful monitoring is recommended.
AI summary of the abstract below.
| Journal | Rev Med Suisse, 2025 |
|---|---|
| Citations | 0 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Chronic Kidney Disease |
Abstract
GLP1 agonists are the emerging fourth pillar of nephroprotection in type 2 diabetes (T2D), alongside renin-angiotensin system blockers, sodium-glucose cotransporter 2 inhibitors, and finerenone (a non-steroidal mineralocorticoid receptor antagonist). The FLOW study showed that semaglutide 1 mg weekly prescribed in T2D patients with moderate to severe renal disease resulted in a 24 % reduction in the risk of a major renal event (NNT: 20) after a median follow-up of 3.4 years and a 20 % reduction in the relative risk of all-cause mortality (NNT: 39). Tirzepatide (a dual GLP1-GIP agonist) shows promising potential, but further data are awaited. However, their use requires caution, especially with regard to gastrointestinal adverse effects and the risk of muscle loss. A multidisciplinary approach remains essential to optimize their efficacy and safety.
Verbatim abstract via PubMed 40443145 ↗